Bioequivalence of Alendronate and Vitamin D3 in a Combination Tablet Versus Corresponding-Dose Individual Tablets in Healthy Taiwanese Volunteers, Determined Using a Novel Plasma Alendronate Assay

D. Hamish Wright, PhD1,*, Ramon Mols, BSc2, Kevin R Brown, BA3, Geng-Chang Yeh, MD, PhD4, Eric Woolf, PhD1, Lisa Hickey, MS3, Stefan Zajic, PhD1

1 Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey
2 3D-PharmXchange Maidstone, 48a 5026SK Tilburg, the Netherlands
3 Former employee of Merck & Co., Inc., Kenilworth, New Jersey
4 Clinical Research Center, Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan

Introduction

Osteoporosis is estimated to affect 200 million women worldwide1 and causes an estimated 9.0 million fractures annually.2 In Taiwan, osteoporosis and associated age-related fractures are a major public health problem. The Nutrition and Health Survey in Taiwan, conducted in 2005 to 2008, found prevalence rates of osteoporosis of 23.9% in men and 38.3% in women aged 50 years and older.3 The prevalence rate of vertebral fractures in urban cities in Taiwan has been reported as 12.5% in men and 20% in women aged 65 years and older.4 The incidence of hip fractures was reported to increase between 1996 and 2002, from 496 to 644 per 100,000 persons per year in Taiwan’s elderly population (aged 65 years and older).5

Providing adequate daily calcium and vitamin D is considered a safe and inexpensive way to help reduce fracture risk for all individuals,6 and optimal vitamin D status appears necessary to maximize the response to antiresorptive therapy.7 The antifracture effects of vitamin D supplementation also appear to be above and above those of calcium supplements, which are often given concurrently.8 Vitamin D deficiency (ie, 25-hydroxyvitamin D [25(OH)D] < 20 ng/mL) is common worldwide, with mean population levels of < 20 ng/mL reported in 37.3% of 195 studies published between 1990 and 2011 involving more than 168,000 patients in 44 countries.9 In older adults living in a northern Taiwan community, the mean 25(OH)D level was 39.9 ng/mL and 31% of the 215 participants had 25(OH)D levels < 20 ng/mL.10 In recent years there has been considerable debate regarding what

* Address correspondence to: D. Hamish Wright, PhD, Merck Research Laboratories, Merck/MSD, K15-3F-395, 2000 Galloping Hill Rd, Kenilworth, NJ 07033.
E-mail address: hamish.wright@merck.com (D.H. Wright).
constitutes an optimal vitamin D status, with osteoporosis guidelines varying in their recommendations for minimal serum 25(OH)D levels. A minimal serum 25(OH)D level of 20 ng/mL or 30 ng/mL is currently recommended for the general population, and a level of 30 ng/mL for fragile elderly patients who are at elevated risk for falls and fracture, with supplementation of 800 to 1000 IU/d for elderly adults with suboptimal levels.

Currently available pharmacologic options for osteoporosis approved by the Taiwan Food and Drug Administration include bisphosphonate alendronate (ALN). Treatment with ALN has been shown to increase bone mass and reduce the incidence of fractures, including hip and vertebral fractures, in postmenopausal women with osteoporosis. Combination tablets, including a once-weekly formulation of ALN 70 mg plus vitamin D3 (either 2800 or 5600 IU) in a single tablet, have been developed to ensure that patients with osteoporosis receiving treatment with ALN also receive adequate vitamin D3 to help reduce the risk of vitamin D insufficiency and deficiency. Previous open-label, 2-period, crossover studies showed that ALN/vitamin D3 combination tablets (either 2800 or 5600 IU vitamin D3) were bioequivalent to an 70-mg ALN tablet with respect to ALN bioavailability, and that the bioavailability of vitamin D3 was similar in the combination tablets and when vitamin D3 was administered alone.

The objective of our study (protocol No. 330-00) was to demonstrate bioequivalence between 70 mg ALN/5600 IU vitamin D3 (ALN/D5600) combination tablets and coadministration of corresponding doses of 70 mg ALN and 5600 IU vitamin D3 (2 x 2800 IU) as individual tablets, in healthy male and female Asian volunteers, to support registration in Taiwan, and to assess safety and tolerability. Of note, the present study used a newly developed, sensitive plasma assay to determine bioequivalence based on the assessment of the pharmacokinetic (PK) characteristics of ALN in plasma, rather than the total urinary excretion method that has been used historically.

Methods

Participants

Adults aged 18 to 85 years, in good health (based on medical history, physical examination, vital sign measurements, and laboratory safety tests), and with a body mass index ≤ 30 were eligible. Women with reproductive potential required a negative pregnancy test and use of appropriate contraception other than oral or hormone-based methods 14 days before study entry through 14 days poststudy. Volunteers were excluded if they had an estimated creatinine clearance ≤ 80 mL/min based on the Cockcroft-Gault equation; were unable to refrain from using any medication, beginning approximately 2 weeks (or 5 half-lives, whichever was longer) before administration of the first dose of study drug; used active vitamin D3 compounds within 10 days before study entry; received a high dose of vitamin D3 (> 5000 IU) within 4 weeks before study entry; or had a 25(OH)D level < 15 ng/mL at screening. Subjects were also excluded if they received regular, prolonged sun exposure and were unable to avoid this exposure during the study. Subjects were required to limit direct sunlight exposure at least 10 days before the first dose and throughout the study, to apply sunscreen (at least 45 SPF) if anticipating exposure to direct sunlight for > 1 hour, and to avoid most dairy products, vitamin D3-fortified foods, and foods known to be high in vitamin D3.

Study design

This was a single-dose, open-label, randomized, 2-period, crossover study to establish bioequivalence between ALN/D5600 combination tablets and coadministration of corresponding doses of 70 mg ALN and 5600 IU vitamin D3 (2 x 2800 IU) as individual tablets in healthy male and female Asian volunteers, to support registration in Taiwan. Subjects were assigned an allocation number for open-label treatment using a computer-generated allocation schedule. In the 2 treatment periods, subjects received 1 of 2 single-dose oral treatments in a randomized order: 1 tablet of ALN/D5600, or 1 tablet of 70 mg ALN and 2 tablets of 2800 IU vitamin D3. For both treatments, subjects fasted overnight for at least 8 hours, with the exception of water, which was restricted for 1 hour before and 1 hour after study-drug administration. All doses of the study drug were administered with 240 mL water. There was a minimum 12-hour washout interval between treatments. Blood samples for determination of plasma ALN concentrations were obtained predose and up to 24 hours postdose in both treatment periods for all enrolled subjects. For the first 40 subjects, blood samples for determination of serum vitamin D3 (cholecalciferol) were obtained predose and up to 96 hours postdose. Subjects were housed in the study unit and not exposed to direct sunlight from 24 hours predose to 24 hours postdose (96 hours postdose for subjects providing serum vitamin D3 samples), including the duration of the PK sampling periods; food provided contained minimal, if any, vitamin D3.

The protocol was approved by the ethical review committee at the study center and conducted in accordance with the guidelines for Good Clinical Practice. All participants provided written informed consent.

Assessments

Blood samples for determination of plasma ALN concentrations were collected predose and 10, 20, 30, 40, and 50 minutes, and 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, and 24 hours postdose. Plasma samples were assayed by PharmaNet Canada, Inc. (Québec, Canada), using a validated HPLC method with a lower limit of quantification of 100 pg/mL. The analyte and its internal standard alendronic acid-d6 were extracted from a 0.2 mL aliquot of human plasma prepared with K2 EDTA, using a protein precipitation step. The extracted samples were injected into a liquid chromatograph equipped with a Zorbax 300-SCX (Agilent, Santa Clara, CA, USA), 50 x 3 mm, 5 μm column. The mobile phase A and B were mixtures of Milli-Q® type water and acetonitrile with ammonium acetate and glacial acetic acid at different proportions. The detection method used was tandem mass spectrometry.

Within-run accuracy and precision evaluations of the assay were performed by analyzing replicate concentrations of alendronic acid in human EDTA K2 plasma. The run consisted of a calibration curve plus a total of 30 spiked samples; 6 replicates of each of the lower and higher limits of quantitation; and low, medium, and high quality control samples. The within-run coefficients of variation ranged between 1.27% and 4.47%. The within-run percentages of bias ranged between –4.19% and 6.34%. The data meet the pre-established acceptance criteria. The assay was demonstrated to be selective for alendronic acid; common over-the-counter medications as well as vitamin D3 were confirmed not to interfere with the analysis.

Blood samples for determination of serum vitamin D3 concentrations were collected at –18, –12, and –6 hours predose, and 1, 2, 4, 6, 8, 9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 15, 16, 18, 20, 24, 48, 72, and 96 hours postdose. Serum samples for vitamin D3 concentrations were assayed using a validated HPLC/tandem mass spectrometry method with an lower limit of quantification of 0.50 ng/mL.

Plasma ALN and serum vitamin D3 concentrations and actual sampling times relative to the time of dose were used to determine
noncompartmental PK parameters using WinNonlin Professional (version 5.2.1) (Certara, Princeton, NJ, USA). Individual baseline vitamin D3 concentration adjustments were made using arithmetic mean vitamin D3 concentrations at −18, −12, and −6 hours before dosing. Baseline adjusted vitamin D3 concentrations were obtained by subtracting the arithmetic mean predose vitamin D3 concentration from each individual postdose sample.

Safety and tolerability were assessed by the daily recording of adverse experiences (AEs) throughout the study. A complete physical examination was performed at pre- and poststudy visits, and complete vital signs were obtained at prestudy, before each study-drug administration, and poststudy. Laboratory safety tests, including serum chemistry, hematology, and urinalysis, were performed on samples obtained at the prestudy visit (approximately 2–4 weeks before the first study drug administration) after at least an 8-hour fast.

Statistical Analysis

**Sample size and power**

If the true geometric mean ratio (GMR) (ALN/D5600:ALN + vitamin D3) for the AUC\(_{0-\text{last}}\) and C\(_{\text{max}}\) of ALN was 0.99 and 0.95, respectively, then a sample size of 60 subjects would provide this study with $>90\%$ probability of observing the 90% CIs of 2 ALN end points to be contained within a range of 0.80 to 1.25, assuming a nonnegative correlation between the 2 test statistics for AUC\(_{0-\text{last}}\) and C\(_{\text{max}}\) of ALN. If the true GMR for the AUC\(_{0-\text{last}}\) and C\(_{\text{max}}\) of vitamin D3 was 0.94, then a sample size of 36 subjects would provide this study with $>90\%$ probability of observing the 90% CIs of the 2 end points to be contained within the range of 0.80 to 1.25, assuming a nonnegative correlation between the 2 test statistics for AUC\(_{0-\text{last}}\) and C\(_{\text{max}}\). For these calculations, the within-subject SD of $\sim 0.20$ (log scale) for the AUC\(_{0-\text{last}}\) and C\(_{\text{max}}\) of vitamin D3 was obtained from internal data (MK-0217A P253). The within-subject SD of 0.30 (log scale) for the AUC\(_{0-\text{last}}\) and C\(_{\text{max}}\) of ALN was obtained from Rhim et al. A nonnegative correlation among the 4 primary end points was assumed for the calculations.

Statistical methods

Statistical and PK analysis was conducted by Cytel Inc. (Cambridge, MA, USA). There were 4 primary end points in this study: ALN AUC\(_{0-\text{last}}\), ALN C\(_{\text{max}}\), vitamin D3 AUC\(_{0-\text{last}}\) and vitamin D3 C\(_{\text{max}}\). The PK parameters for ALN (AUC\(_{0-\text{last}}\), AUC\(_{0-\text{inf}}\), and C\(_{\text{max}}\) and vitamin D3 (unadjusted AUC\(_{0-\text{last}}\) and C\(_{\text{max}}\)) following a single oral dose of ALN/vitamin D3 combination tablet or coadministration of ALN + vitamin D3 were compared using a linear mixed-effects model appropriate for a 2-period, crossover design. The model contained period and treatment as fixed effects, and subject as a random effect. A log transformation was applied to the AUC and C\(_{\text{max}}\) before analysis.

The GMR of ALN AUC\(_{0-\text{last}}\), ALN AUC\(_{0-\text{inf}}\), ALN C\(_{\text{max}}\), and vitamin D3 AUC\(_{0-\text{last}}\) and vitamin D3 C\(_{\text{max}}\), unadjusted for endogenous vitamin D3, were compared and bioequivalence defined by the 90% CI (based on the $r$-distribution) of the GMR for each primary end point being contained within prespecified bounds (ie, 0.80–1.25).

Data were also examined for departures from the assumptions of the statistical model and the use of a distribution-free method considered if a serious departure from the assumptions of the model was observed. Normality assumptions for the linear mixed model were not met due to several extreme values. Therefore, a nonparametric analysis that requires no normality assumption about the distribution of the data was also conducted for the ALN AUC\(_{0-\text{last}}\), AUC\(_{0-\text{inf}}\), and C\(_{\text{max}}\) data. Specifically, the Hodges-Lehmann point estimate and the associated 90% CI were calculated for the median of all pairwise differences of log-transformed AUC\(_{0-\text{last}}\), AUC\(_{0-\text{inf}}\), and C\(_{\text{max}}\). The point estimate and 90% CI were then exponentiated to the linear scale to obtain the estimate of median ratio and the associated 90% CI.

Descriptive statistics were provided for other plasma PK parameters ($T_{\text{max}}$ and $t_{\frac{1}{2}}$). Minimum, median, and maximum were provided for all PK parameters. In addition, the %CV for AUC and C\(_{\text{max}}\) were calculated according to the following formula: $100 \times \sqrt{\text{exp}(s^2)} – 1$, where $s^2$ is the observed variance on the natural log scale. Harmonic mean and jackknife SD were provided for apparent $t_{\frac{1}{2}}$.

**Results**

**Subjects**

From March 2012 through May 2012, 69 healthy male ($n = 53$) and female ($n = 16$) volunteers (mean [range] age 29.0 [20–54] years; height, 169.8 [150.0–192.0] cm; weight 56.0 [45.0–95.0] kg; and body mass index, 22.9 [17.4–29.3]) were enrolled and were included in the safety evaluation; 68 subjects completed the study per protocol and were included in the PK analysis. One male subject was discontinued from the study after dosing with coadministered ALN + vitamin D3 in the first treatment period due to noncompliance with the protocol.

**PK of ALN**

Mean plasma concentration–time profiles of ALN following administration of an ALN/D5600 combination tablet and coadministration of corresponding doses of ALN and vitamin D3 as individual tablets are shown in Figure 1A. One subject (a woman aged 29 years) had no measurable plasma concentrations for ALN on administration of the reference formulation (ALN + vitamin D3), so was excluded from the PK analysis for ALN.

Summary statistics for PK parameters of plasma ALN for subjects with measurable PK in both treatment periods are shown in Table I. The 90% CIs of the GMR for ALN AUC\(_{0-\text{last}}\) and C\(_{\text{max}}\) were not contained within the prespecified bioequivalence bounds (ie, 0.80–1.25); the upper 90% CIs slightly exceeded 1.25 with actual values of 1.253 and 1.289, respectively. However, the 90% CI of the GMR for ALN AUC\(_{0-\text{inf}}\) was contained within the bounds. The median $T_{\text{max}}$ (1.2 hours and 1.0 hour for ALN/D5600 and ALN + vitamin D3, respectively) and harmonic mean apparent $t_{\frac{1}{2}}$ (7.8 hours and 7.7 hours, respectively) for plasma ALN were comparable between treatments.

ALN exhibited higher within-subject variability for both AUC and C\(_{\text{max}}\) (%CV, 50%–51%) than was anticipated from the literature (%CV, ~30% for both AUC and C\(_{\text{max}}\)) when the study was designed. With the nonparametric analysis that requires no normality assumption about the distribution of the data and is less sensitive to extreme values, the 90% CI for the ratio of the medians for AUC\(_{\text{last}}\) and AUC\(_{\text{inf}}\) was within the bounds of bioequivalence (ie, 0.80–1.25) (Table II). The upper bound of the 90% CI for ALN C\(_{\text{max}}\) median ratio marginally exceeded 1.25.

The individual ratios, GMRs, and corresponding 90% CIs of the plasma AUC\(_{0-\text{last}}\), AUC\(_{0-\text{inf}}\), and C\(_{\text{max}}\) for ALN are shown in Figure 2A.

**PK of Vitamin D3**

**Baseline unadjusted vitamin D3**

Mean plasma concentration–time profiles of serum unadjusted vitamin D3 following administration of an ALN/D5600 combination tablet and coadministration of corresponding doses of ALN and vitamin D3 as individual tablets are shown in Figure 1B.
respectively) and harmonic mean apparent t1/2 (29.9 hours and 8.8 hours, respectively) for baseline unadjusted serum vitamin D3 were comparable between ALN/D5600 and ALN + vitamin D3 treatments.

The individual ratios, GMRs, and corresponding 90% CIs of the serum unadjusted AUC0–80h and Cmax for vitamin D3 are shown in Figure 2B.

**Baseline adjusted vitamin D3**

For most subjects, postdose vitamin D3 levels were above predose levels. However, in some subjects, vitamin D3 levels declined to such an extent that at 80 hours postdose, they had substantially lower vitamin D3 concentrations than their predose values. In some instances, this decline resulted in negative concentration values when adjusted for predose vitamin D3. The GMRs (90% CI) of serum vitamin D3 after baseline correction were: 1.101 (90% CI, 0.895–1.356) and 1.049 (90% CI, 0.893–1.231) for AUC0–80h and Cmax, respectively. Whereas both point estimates and the entire 90% CI for Cmax were within the prespecified bioequivalence bounds of 0.80 to 1.25, the upper limit of the 90% CI for AUC0–80h fell outside these bounds.

**Safety and Tolerability**

Of the 69 subjects included in the safety analysis (1 of whom did not receive the combination tablet), 51 reported a total of 128 clinical AEs, of which 125 were considered by the investigator to be possibly related to the study drug. All AEs were transient and considered mild in intensity by the investigator. There were no serious AEs reported and no subjects discontinued because of an AE. Two laboratory AEs were reported at prestudy: alanine aminotransferase increased for 1 subject and aspartate aminotransferase increased for a second subject. There were no consistent treatment-related changes in routine clinical safety parameters, including vital signs and physical examination.

The most common drug-related AEs were arthralgia (reported by 25 and 27 subjects after receiving ALN/D5600 and ALN + vitamin D3, respectively), pyrexia (12 vs 10 subjects), and headache (9 vs 10 subjects). Gastrointestinal disorders were reported in 4 and 6 patients, respectively, and included abdominal distension, diarrhea, vomiting (all 1 subject each) and toothache (2 subjects) in the ALN/D5600 group, and diarrhea (5 subjects), toothache (2 subjects), and nausea (1 subject) in the ALN + vitamin D3 group. There were no clinically meaningful differences in

### Table 1

Summary results for pharmacokinetic parameters of plasma alendronate (ALN) and serum vitamin D3 following administration of a 70 mg ALN/5600 IU vitamin D3 (D5600) combination tablet or corresponding doses of ALN and vitamin D3 as individual tablets.

| Pharmacokinetic parameter | ALN/D5600 combination tablet | ALN + vitamin D3 coadministration | ALN/D5600:ALN + vitamin D3 | %CV
|---------------------------|-----------------------------|----------------------------------|---------------------------|-------|
|                           | n      | GM     | 95% CI       | n         | GM     | 95% CI       | GMR 90% CI | %CV
| Plasma ALN                |        |        |              |            |        |              |                |
| AUC0–inf., ng·h/mL        | 67     | 111.71 | 96.72–129.03 | 67         | 103.08 | 88.20–120.48 | 1.084 0.937–1.253 | 50.45 |
| AUC0–tmax., ng·h/mL       | 67     | 116.73 | 101.18–134.66| 67         | 108.02 | 92.63–125.98 | 1.081 0.935–1.249 | 50.21 |
| Cmax , ng/mL              | 67     | 36.48  | 31.46–42.30  | 67         | 32.82  | 28.25–38.13  | 1.112 0.959–1.289 | 51.29 |
| T1/2, h                   | 67     | 1.2    | 0.5–2.0      | 67         | 1.0    | 0.3–3.0      | –                  | –     |
| Serum vitamin D3          |        |        |              |            |        |              |                |
| AUC0–inf., ng·h/mL        | 40     | 382.81 | 318.83–459.62| 40         | 401.86 | 351.01–460.08| 0.953 0.827–1.098 | 37.68 |
| Cmax , ng/mL              | 40     | 10.45  | 8.86–12.32   | 40         | 10.64  | 9.29–12.19   | 0.982 0.854–1.130 | 37.14 |
| T1/2, h                   | 40     | 12.5   | 9.0–24.1     | 40         | 13.5   | 10.0–16.0    | –                  | –     |

GM = geometric mean.

* GM computed from least squares estimate from a linear mixed-effects model performed on the natural log-transformed values.

† %CV, derived from variance components, provides an estimate of the pooled within-subject coefficient of variation.

‡ Harmonic mean and jackknife SD provided for apparent t1/2.

Figure 1. (A) Arithmetic mean (upper SD) plasma alendronate (ALN) and (B) serum vitamin D3 for subjects with measurable PK data in both treatment periods are shown in Table I. The 90% CIs of the GMR for vitamin D3 AUC0–80h and Cmax, unadjusted for endogenous vitamin D3, were contained within the prespecified bioequivalence bounds (ie, 0.80–1.25). The median Tmax (12.5 hours and 13.5 hours, respectively) and harmonic mean apparent t1/2 (29.9 hours and 8.8 hours, respectively) for baseline unadjusted serum vitamin D3 were comparable between ALN/D5600 and ALN + vitamin D3 treatments.

The individual ratios, GMRs, and corresponding 90% CIs of the serum unadjusted AUC0–80h and Cmax for vitamin D3 are shown in Figure 2B.

Baseline adjusted vitamin D3

For most subjects, postdose vitamin D3 levels were above predose levels. However, in some subjects, vitamin D3 levels declined to such an extent that at 80 hours postdose, they had substantially lower vitamin D3 concentrations than their predose values. In some instances, this decline resulted in negative concentration values when adjusted for predose vitamin D3. The GMRs (90% CI) of serum vitamin D3 after baseline correction were: 1.101 (90% CI, 0.895–1.356) and 1.049 (90% CI, 0.893–1.231) for AUC0–80h and Cmax, respectively. Whereas both point estimates and the entire 90% CI for Cmax were within the prespecified bioequivalence bounds of 0.80 to 1.25, the upper limit of the 90% CI for AUC0–80h fell outside these bounds.

Safety and Tolerability

Of the 69 subjects included in the safety analysis (1 of whom did not receive the combination tablet), 51 reported a total of 128 clinical AEs, of which 125 were considered by the investigator to be possibly related to the study drug. All AEs were transient and considered mild in intensity by the investigator. There were no serious AEs reported and no subjects discontinued because of an AE. Two laboratory AEs were reported at prestudy: alanine aminotransferase increased for 1 subject and aspartate aminotransferase increased for a second subject. There were no consistent treatment-related changes in routine clinical safety parameters, including vital signs and physical examination.

The most common drug-related AEs were arthralgia (reported by 25 and 27 subjects after receiving ALN/D5600 and ALN + vitamin D3, respectively), pyrexia (12 vs 10 subjects), and headache (9 vs 10 subjects). Gastrointestinal disorders were reported in 4 and 6 patients, respectively, and included abdominal distension, diarrhea, vomiting (all 1 subject each) and toothache (2 subjects) in the ALN/D5600 group, and diarrhea (5 subjects), toothache (2 subjects), and nausea (1 subject) in the ALN + vitamin D3 group. There were no clinically meaningful differences in
tolerability between the ALN/D5600 combination tablet and the coadministered dose of ALN and vitamin D₃.

**Discussion**

Although the 90% CIs of the observed GMRs for the plasma AUC₀–last and Cₘₐₓ of ALN for subjects with measurable PK in both treatment periods were not all contained within the prespecified bounds for bioequivalence (ie, 0.80–1.25), the 90% CI of the observed GMR for AUC₀–∞ of ALN was within the bounds. In addition, the 90% CI of the ratio of medians for AUC₀–∞ obtained from the nonparametric analysis was within the prespecified bounds. The ALN/D5600 combination tablet and coadministration of ALN + vitamin D₃ resulted in similar plasma concentration-time profiles (Figure 1). This is supported by the fact that for both GMRs the AUC₀–last and Cₘₐₓ were within the lower bound of the 90% CI of ALN AUC₀–last and Cₘₐₓ (there was only a minor excursion of the upper bound of the 90% CI of ALN AUC₀–last and Cₘₐₓ), and the entire 90% CI for AUC₀–∞ was within the bioequivalence bounds (ie, 0.80–1.25).

The observed differences between ALN AUC₀–last and Cₘₐₓ are not believed to be clinically significant, in that the slightly higher AUC₀–last and Cₘₐₓ of the ALN/D5600 combination tablet would not be expected to result in an additional safety risk or to have an influence on efficacy compared with concomitant ALN + vitamin D₃. This is because the differences were small and thus would likely fall within the range experienced among the broad population of patients using ALN, and because of the mechanism of action of ALN, which relies on its deposition in bone. Incorporation of ALN in bone over time is correlated clinically with increased bone mass and reduced fracture risk, such that small differences in AUC or Cₘₐₓ are unlikely to have a major effect. In addition, based on the highly variable drug characteristics of ALN and using the proposed bioequivalence approach of the European Medicines Agency for high variability values (intrasubject variability > 30%), the Cₘₐₓ of ALN falls within the expanded CI of 0.698 to 1.432. The highly variable drug status of ALN was not prespecified in the hypothesis because this was the first study conducted by the sponsor to employ a newly developed assay for plasma ALN. For this reason, internal data on which to base variability estimates were lacking, and data from the literature on ALN were limited in this regard.

The GMR and 90% CIs for unadjusted serum vitamin D₃ for ALN₀–80h and Cₘₐₓ were within the prespecified bioequivalence bounds. After baseline correction of serum vitamin D₃, both point estimates and the entire 90% CI for Cₘₐₓ were within the prespecified bounds; however, the upper limit of the 90% CI for ALN₀–80h fell outside these bounds. This was because some subjects had lower serum vitamin D₃ concentrations at 80 hours postdose than at predose. The likely explanation for this is the restrictions that were placed on subjects to prevent exposure to vitamin D₃ except for study treatment, including the avoidance of sun exposure and a diet containing minimal, if any, vitamin D₃. The baseline adjusted approach attempts to separate the contribution of the administered vitamin D₃ from endogenous vitamin D₃ levels on an individual basis, and in doing so, also adjusts for potential differences in baseline vitamin D₃ levels across periods. However, this approach assumes that the endogenous level will remain constant, which appeared to be incorrect for some subjects. The PK parameters ALN₀–80h and Cₘₐₓ obtained from the data unadjusted for baseline vitamin D₃ concentrations are therefore favored...
because this approach requires no assumptions; these data also agree with those presented previously.16

Historically, the primary PK parameter of ALN was urinary excretion of ALN. This was because plasma concentrations were too low for analysis and elimination of bioavailable ALN is essentially entirely via urinary excretion.19 However, urinary analysis of ALN requires complex processes, is labor intensive, and typically requires more than 200 subjects to demonstrate bioequivalence.16 Recently, HPLC-MS/MS detection has been used to measure plasma ALN levels. Use of a plasma-based assessment required fewer subjects to demonstrate bioequivalence compared with urine-based assessments.38 Once the extreme values in the ALN data were accommodated, the data generated from this study are in good agreement with those published previously using a urine-based approach to demonstrate bioequivalence,16 which supports the applicability of the plasma ALN assay. Because the plasma $t_{1/2}$ of ALN is long (up to 10 years), calculation of the supports the applicability of the plasma ALN assay. Because the plasma $t_{1/2}$ of ALN is long (up to 10 years), calculation of the apparent terminal $t_{1/2}$ and therefore the $AUC_{0-\infty}$ may be underestimated. Hence, the $AUC_{0-\text{last}}$ was proposed as the primary PK end point upon which to assess bioequivalence for ALN. There were no clinically meaningful differences in tolerability between the ALN/D5600 tablet and the coadministration of ALN + vitamin D$_3$. Although the combination tablet showed slightly higher $C_{\text{max}}$ and $AUC_{0-\text{last}}$ for ALN, the safety profile remained consistent with that of the marketed drug.

Conclusions

In this study of healthy male and female volunteers in Taiwan, the ALN/D5600 combination tablet was considered bioequivalent to coadministration based on ALN $AUC_{0-\infty}$ and nonparametric $AUC_{0-\text{last}}$ and unadjusted vitamin D$_3$ $AUC_{0-\text{last}}$ and $C_{\text{max}}$. The magnitude of the difference between ALN/D5600 and ALN + vitamin D$_3$ for ALN $AUC_{0-\text{last}}$ and $C_{\text{max}}$ was not considered to be clinically significant, and both parameters fall within the expanded CIs of the European Medicines Agency’s proposed bioequivalence approach for high variability samples. The combination tablet was well tolerated, with no serious AEs reported, and is comparable to the coadministration of corresponding doses of ALN and vitamin D$_3$.

Acknowledgments

Medical writing support was provided by Annette Smith, PhD, of Complete Medical Communications, funded by Merck & Co., Inc. D.H. Wright and S.C. Zajic contributed in the study design, D.H. Wright, R. Mols, K. Brown, E. Woolf, G.-C. Yeh, L. Hickey and S.C. Zajic contributed in the collection, analysis and interpretation of data, D.H. Wright, R. Mols, K. Brown, and S.C. Zajic contributed in writing of the report, D.H. Wright, E. Woolf, G.-C. Yeh, and S.C. Zajic contributed in decision to submit the article for publication.

Conflicts of Interest

This study was sponsored by Merck & Co., Inc. Lata Maganti provided support in the design and statistical analyses for the study. The following authors are, or were at the time of the study, employees of the study sponsor (Merck): D.H. Wright, K. Brown, E. Woolf, S. Zajic, and R. Mols. L. Hickey was an employee of Cytel, Inc at the time of the study and is a former employee of Merck & Co, Inc. The following authors own stock/shares in Merck: D.H. Wright, S. Zajic, E. Woolf, and K. Brown. D.H. Wright has received research support from Merck. The authors have indicated that they have no other conflicts of interest regarding the content of this article.

References

1. International Osteoporosis Foundation. Facts and statistics, 2014. www.iofbonehealth.org/facts-statistics. Accessed November 19, 2014.
2. Johneil O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733.
3. Lin YC, Pan WH. Bone mineral density in adults in Taiwan: results of the Nutrition and Health Survey in Taiwan 2005-2008 (NHSHT 2005-2008). Asia Pac J Clin Nutr. 2011;20:283–291.
4. Tsai K, Twu S, Cheng P, et al. Prevalence of vertebral fractures in Chinese men and women in urban Taiwanese communities. Calcif Tissue Int. 1996;59:249–253.
5. Shao CJ, Hisieh YH, Tsai CH, Lai KA. A nationwide seven-year trend of hip fractures in the elderly population of Taiwan. Bone. 2009;44:125–129.
6. National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2014.
7. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med. 2009;169:551–561.
8. Bergman GJ, Fan T, McFetridge JT, Sen SS. Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: a meta-analysis. Curr Med Res Opin. 2010;26:1193–1201.
9. Hilger J, Friedel A, Herr R, et al. A systematic review of vitamin D status in populations worldwide. Br J Nutr. 2014;111:23–45.
10. Chang CI, Chan DC, Kuo KN, et al. Vitamin D insufficiency and frailty syndrome in older adults living in a Northern Taiwan community. Arch Gerontol Geriatr. 2010;50(Suppl 1):S77–S81.
11. Bouillon R, Van Schoor NM, Gieles E, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab. 2013;98:E1283–E1304.
12. Rizzoli R, Boonen S, Brandi ML, et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin. 2013;29:305–313.
13. Hwang JS, Chan DC, Chen JF, et al. Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab. 2014;32:10–16.
14. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535–1541.
15. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082.
16. Denker AE, Lazarus N, Porras A, et al. Bioavailability of alendronate and vitamin D(3) in an alendronate/vitamin D(3) combination tablet. J Clin Pharmacol. 2011;51:1439–1448.
17. Food and Drug Administration. Guidance for industry: statistical approaches to establishing bioequivalence. 2001. http://www.fda.gov/downloads/Drugs/Guidances/ucm070244.pdf. Accessed September 5, 2015.
18. Rhim SY, Park JH, Park YS, et al. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. Clin Ther. 2009;31:1037–1045.
19. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet. 1999;36:315–328.
20. European Medicines Agency. EMEA Guideline on the Investigation of Bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/Curr **. London: European Medicines Agency; 2010.